| Name | Title | Contact Details |
|---|
Immunovant is a biopharmaceutical company committed to developing innovative therapies that not only treat the symptoms, but modify the course of autoimmune diseases. Our primary investigational product candidate is RVT-1401, a human recombinant anti-FcRn monoclonal antibody that is being developed with a focus on patient need, and may be applicable to a wide array of autoimmune diseases. We are currently assessing RVT-1401 in a single and multiple ascending dose Phase 1 clinical trial. We plan on initiating a number of patient-based studies in early 2019, focusing on Myasthenia gravis (MG) and other IgG-mediated diseases. We also seek to continue expanding our pipeline, ultimately transforming the lives of patients with autoimmune diseases.
Linden Labs is a San Francisco, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Gemelli Biotech leverages leading biological discoveries related to the microbiome to provide non-invasive precision diagnostics which enable clinicians to definitively detect scientifically validated biomarkers and optimally treat GI diseases including SIBO, IMO, excess hydrogen sulfide and post-infectious IBS.
Since 1995, BGG (Beijing Gingko Group) has been a global leader in the manufacture and sourcing of clinically-supported ingredients for the dietary supplement, cosmetics, and food and beverage industries. BGG has provided the highest quality, natural ingredients to clients world-wide. We start with the highest quality, wild-crafted, organic and non-GMO raw materials and produce natural health products and nutritional solutions that aid and enhance people`s well-being and quality of life. BGG specializes in organic fruit extracts, marine botanicals, natural vitamins, herbal extracts, natural sweeteners and flavor enhancers.
NextCure is a fully integrated biotechnology company discovering and developing first-in-class immunotherapy-based biologics for cancer and other diseases. The company is focused on understanding biological pathways and leveraging our FIND-IOTM technology to discover, validate and build a proprietary pipeline. We believe identifying and targeting immune pathways will promote identification of effective targets for mediating sustained immunity leading to improved outcomes for cancer patients.